Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.

× No keyword cloud information.

17 in total

1. Growth deceleration in a girl treated with imatinib.

Authors: Tomiko Kimoto; Masami Inoue; Keisei Kawa
Journal: Int J Hematol Date: 2009-01-20 Impact factor: 2.490

2. Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.

Authors: Philipp Ivanyi; Thomas Winkler; Anika Grosshennig; Christoph Reuter; Axel S Merseburger; Arnold Ganser; Viktor Grünwald
Journal: World J Urol Date: 2010-05-05 Impact factor: 4.226

3. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.

Authors: Kyu-Hyun Yang; Si-Young Park; Sang-Won Park; Soon-Hyuck Lee; Seung-Beom Han; Woong-Kyo Jung; Suk-Jin Kim
Journal: J Bone Miner Metab Date: 2010-07-06 Impact factor: 2.626

Review 4. Endocrine side effects of broad-acting kinase inhibitors.

Authors: Maya B Lodish; Constantine A Stratakis
Journal: Endocr Relat Cancer Date: 2010-08-16 Impact factor: 5.678

5. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.

Authors: Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos
Journal: Clin Lymphoma Myeloma Leuk Date: 2016-08

Review 6. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors: Maya B Lodish
Journal: J Clin Endocrinol Metab Date: 2013-02-28 Impact factor: 5.958

Review 7. Skeletal sequelae of cancer and cancer treatment.

Authors: Charles J Stava; Camilo Jimenez; Mimi I Hu; Rena Vassilopoulou-Sellin
Journal: J Cancer Surviv Date: 2009-05-02 Impact factor: 4.442

8. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors: Tariq I Mughal; Andrew Schrieber
Journal: Biologics Date: 2010-12-02

9. SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Authors: Cesarina Giallongo; Piera La Cava; Daniele Tibullo; Ignazio Barbagallo; Nunziatina Parrinello; Alessandra Cupri; Fabio Stagno; Carla Consoli; Annalisa Chiarenza; Giuseppe A Palumbo; Francesco Di Raimondo
Journal: BMC Cancer Date: 2013-02-05 Impact factor: 4.430

10. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors: Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal: Ther Clin Risk Manag Date: 2008-02 Impact factor: 2.423